抗 ErbB2 免疫疗法：为癌症治疗努力制造更好的抗体。
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
机构信息
Biotechnology Research and Development, Alfasigma SpA, Rome, Italy.
出版信息
MAbs. 2020 Jan-Dec;12(1):1725346. doi: 10.1080/19420862.2020.1725346.
Abstract
Over the past 3 decades, monoclonal antibodies and their related derivatives, including recently approved antibody-drug conjugates, conquered a central role in cancer therapy because of their contribution to improve survival, time to progression and quality of life of patients compared to chemotherapy protocols. This review summarizes information on approved original and biosimilar products, as well as investigational antibody-based therapeutics, targeting ErbB2. This target has been selected as a paradigmatic example because of its relevant role in sustaining the malignancy of major cancer diseases including, breast, gastric and other chemotherapy-resistant solid tumors. This work analyzes the drivers affecting research and development of next-generation anti-ErbB2 immunotherapeutics, taking into account unmet medical needs and pharmacoeconomic issues related to sustainability. The analysis may help with the design of future research and development strategies.
摘要
在过去的 30 年中，单克隆抗体及其相关衍生物，包括最近批准的抗体药物偶联物，由于其在改善患者生存率、进展时间和生活质量方面的贡献，在癌症治疗中占据了核心地位，与化疗方案相比。这篇综述总结了针对 ErbB2 的已批准的原始和生物类似产品以及正在研究的基于抗体的治疗药物的信息。选择该靶点作为范例，是因为它在维持乳腺癌、胃癌和其他化疗耐药实体瘤等主要癌症疾病的恶性肿瘤中具有重要作用。这项工作分析了影响下一代抗 ErbB2 免疫治疗药物研发的驱动因素，同时考虑了与可持续性相关的未满足的医疗需求和药物经济学问题。该分析有助于设计未来的研发策略。
相似文献
1
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.抗 ErbB2 免疫疗法：为癌症治疗努力制造更好的抗体。
MAbs. 2020 Jan-Dec;12(1):1725346. doi: 10.1080/19420862.2020.1725346.
2
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.拟用曲妥珠单抗生物类似药对比曲妥珠单抗治疗 ERBB2（HER2）阳性转移性乳腺癌患者的总缓解率：一项随机临床试验。
JAMA. 2017 Jan 3;317(1):37-47. doi: 10.1001/jama.2016.18305.
3
Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.单克隆抗体、小分子抑制剂和抗体药物偶联物作为 HER2 抑制剂。
Curr Med Chem. 2021;28(17):3339-3360. doi: 10.2174/0929867327666200908112847.
4
[Current situations and the future prospect of monoclonal antibody products].[单克隆抗体产品的现状与未来前景]
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2014(132):36-46.
5
Clinical development of CT-P10 and other biosimilar cancer therapeutics.CT-P10及其他生物类似药癌症治疗药物的临床开发
Future Oncol. 2017 May;13(15s):31-44. doi: 10.2217/fon-2017-0155.
6
The next generation of antibody-drug conjugates comes of age.新一代抗体药物偶联物已走向成熟。
Discov Med. 2010 Oct;10(53):329-39.
7
The use of monoclonal antibody immunoconjugates in cancer therapy.单克隆抗体免疫缀合物在癌症治疗中的应用。
Adv Exp Med Biol. 1994;353:169-79. doi: 10.1007/978-1-4615-2443-4_16.
8
Treating the HER2 pathway in early and advanced breast cancer.治疗早期和晚期乳腺癌中的 HER2 通路。
Hematol Oncol Clin North Am. 2013 Aug;27(4):751-65, viii. doi: 10.1016/j.hoc.2013.05.007.
9
New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.肿瘤学新前沿：用于治疗乳腺癌的生物类似单克隆抗体。
Expert Rev Anticancer Ther. 2015 Mar;15(3):331-8. doi: 10.1586/14737140.2015.993318. Epub 2014 Dec 25.
10
[An overview of antibody-based cancer therapy].[基于抗体的癌症治疗概述]
Yao Xue Xue Bao. 2012 Oct;47(10):1261-8.
引用本文的文献
1
Unlocking the potential of bispecific ADCs for targeted cancer therapy.解锁双特异性 ADC 用于靶向癌症治疗的潜力。
Front Med. 2024 Aug;18(4):597-621. doi: 10.1007/s11684-024-1072-8. Epub 2024 Jul 23.
2
Biparatopic antibodies: therapeutic applications and prospects.双靶向抗体：治疗应用与前景。
MAbs. 2024 Jan-Dec;16(1):2310890. doi: 10.1080/19420862.2024.2310890. Epub 2024 Mar 4.
3
Emerging biomaterials for tumor immunotherapy.用于肿瘤免疫治疗的新型生物材料。
Biomater Res. 2023 May 16;27(1):47. doi: 10.1186/s40824-023-00369-8.
4
Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy.用于评估新辅助治疗的HER2低表达乳腺癌预后模型的开发与验证
Gland Surg. 2023 Feb 28;12(2):183-196. doi: 10.21037/gs-22-729. Epub 2023 Feb 15.
5
Emerging new therapeutic antibody derivatives for cancer treatment.新兴的癌症治疗用治疗性抗体衍生物。
Signal Transduct Target Ther. 2022 Feb 7;7(1):39. doi: 10.1038/s41392-021-00868-x.
6
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives.人表皮生长因子受体2靶向治疗子宫内膜癌：临床与病理学视角
World J Clin Oncol. 2021 Oct 24;12(10):868-881. doi: 10.5306/wjco.v12.i10.868.
7
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?晚期胃癌中新型HER2靶向治疗：又一次范式转变？
Cancers (Basel). 2021 Apr 1;13(7):1664. doi: 10.3390/cancers13071664.
8
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.一种双价、双特异性 Dab-Fc 抗体分子，用于双重靶向 HER2 和 HER3。
MAbs. 2021 Jan-Dec;13(1):1902034. doi: 10.1080/19420862.2021.1902034.
9
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.试验观察：用于肿瘤适应症的实验性TLR7/TLR8激动剂
Oncoimmunology. 2020 Jul 21;9(1):1796002. doi: 10.1080/2162402X.2020.1796002.
本文引用的文献
1
ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1.ErbB2靶向表观遗传调控：抗体药物偶联物曲妥珠单抗-组蛋白去乙酰化酶抑制剂ST8176AA1的抗肿瘤疗效
Front Oncol. 2020 Jan 23;9:1534. doi: 10.3389/fonc.2019.01534. eCollection 2019.
2
Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2.用于MEDI4276临床生物分析的多重液相色谱-串联质谱法，MEDI4276是一种通过可裂解连接子连接到抗HER-2双特异性人源化抗体的微管溶素类似物抗体药物偶联物。
Antibodies (Basel). 2019 Jan 11;8(1):11. doi: 10.3390/antib8010011.
3
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.用于高效杀伤癌细胞的新型人双特异性适体-抗体偶联物
Cancers (Basel). 2019 Aug 29;11(9):1268. doi: 10.3390/cancers11091268.
4
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.一种新型不对称抗 HER2/CD3 双特异性抗体对 HER2 阳性肿瘤细胞表现出强大的细胞毒性。
J Exp Clin Cancer Res. 2019 Aug 14;38(1):355. doi: 10.1186/s13046-019-1354-1.
5
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.头对头临床试验系统评价：已批准用于癌症的单克隆抗体的概述
J Cancer Res Clin Oncol. 2019 Sep;145(9):2303-2311. doi: 10.1007/s00432-019-02984-2. Epub 2019 Aug 8.
6
FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.基于 FHR4 的免疫偶联物针对 HER2 阳性癌细胞诱导补体依赖性细胞毒性和吞噬作用。
Mol Oncol. 2019 Dec;13(12):2531-2553. doi: 10.1002/1878-0261.12554. Epub 2019 Sep 30.
7
The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.生物类似药在肿瘤学和血液学领域的经济影响：以曲妥珠单抗和利妥昔单抗为例。
Anticancer Res. 2019 Jul;39(7):3971-3973. doi: 10.21873/anticanres.13552.
8
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.肿瘤学中生物类似药单克隆抗体的到来：曲妥珠单抗生物类似药的临床研究。
Br J Cancer. 2019 Jul;121(3):199-210. doi: 10.1038/s41416-019-0480-z. Epub 2019 Jul 1.
9
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.曲妥珠单抗 DM1 治疗局部晚期和转移性实体瘤及 HER2 阳性乳腺癌：一项 1 期剂量递增和扩展研究。
Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27.
10
Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.抗 HER2 靶向阿霉素核壳壳聚糖纳米粒的制备及其用于人乳腺癌的治疗。
Int J Nanomedicine. 2019 Jun 4;14:4105-4121. doi: 10.2147/IJN.S198552. eCollection 2019.
Zotero 插件